Loxo Oncology (LOXO) Stock Price, News & Analysis

Company Overview

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company's preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc. to obtain various rights to TRK inhibitor program and oncology targets; strategic partnership with Illumina, Inc. to develop and commercialize a multi-gene panel for broad tumor profiling; and research collaboration agreement with Veracyte, Inc. to develop medicines for patients with genetically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut.

Key Stats

• Today's Range: $234.66 to $234.66
• 50-Day Range: N/A
• 52-Week Range: $101.70 to $234.93
• Volume: 400 shs
• Average Volume: 565,561 shs
• Market Capitalization: $7.18 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LOXO Stock Analysis - Frequently Asked Questions

How were Loxo Oncology's earnings last quarter?

Loxo Oncology Inc (NASDAQ:LOXO) announced its quarterly earnings data on Thursday, August, 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.15. The biopharmaceutical company earned $42.60 million during the quarter, compared to analyst estimates of $32.36 million. Loxo Oncology had a negative net margin of 43.49% and a negative trailing twelve-month return on equity of 16.42%.

What other stocks do shareholders of Loxo Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Loxo Oncology investors own include Meta Platforms (META), Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), GW Pharmaceuticals (GWPH) and Micron Technology (MU).

Company Calendar

• Last Earnings: 8/09/2018
• Today: 5/02/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:LOXO
• CIK: 1581720
• Web: www.loxooncology.com
• Phone: 203-653-3880
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($5.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-148,870,000.00
• Net Margins: -43.49%
• Pretax Margin: N/A
• Return on Equity: -16.42%
• Return on Assets: -8.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.62
• Quick Ratio: 3.62

Sales & Book Value

• Annual Sales: $21.30 million
• Price / Sales: 337.23
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.63 per share
• Price / Book: 18.58

Miscellaneous

• Outstanding Shares: 30,610,000
• Free Float: N/A
• Market Cap: $7.18 billion
• Optionable: Optionable
• Beta: 2.51